Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort

被引:10
作者
Thomas, Quentin Dominique [1 ,20 ]
Boussere, Amal [2 ]
Classe, Jean-Marc [3 ]
Pomel, Christophe [4 ]
Costaz, Helene [5 ]
Rodrigues, Manuel [6 ]
Ray-Coquard, Isabelle [7 ]
Gladieff, Laurence [8 ]
Rouzier, Roman [9 ]
Rouge, Thibault De La Motte [10 ]
Gouy, Sebastien [11 ]
Barranger, Emmanuel [12 ]
Sabatier, Renaud [13 ]
Floquet, Anne [14 ]
Marchal, Frederic [15 ]
Guillemet, Cecile [16 ]
Polivka, Valentine [2 ]
Martin, Anne-Laure [17 ]
Colombo, Pierre-Emmanuel [18 ]
Fiteni, Frederic [19 ]
机构
[1] Montpellier Univ, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France
[2] Montpellier Univ, Inst Canc Montpellier, Dept Biometry, Montpellier, France
[3] Inst Cancerol Ouest Ctr Rene Gauducheau, Dept Surg Oncol, St Herblain, France
[4] Univ Clermont Auvergne, Ctr Lutte Canc Jean Perrin, Dept Surg Oncol, Imagerie Mol & Strategies Theranost,UMR,INSERM,UCA, Clermont Ferrand, France
[5] Ctr Georges Francois Leclerc, Dept Surg Oncol, Dijon, France
[6] Inst Curie, Dept Med Oncol, Paris, France
[7] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[8] Inst Claudius Regaud IUCT O, Dept Med Oncol, Toulouse, France
[9] Ctr Francois Baclesse, Dept Surg Oncol, Caen, France
[10] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[11] Gustave Roussy, Dept Surg, Villejuif, France
[12] Ctr Antoine Lacassagne, Dept Surg, Nice, France
[13] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France
[14] Inst Bergonie, Dept Med Oncol, Bordeaux, France
[15] Inst Cancerol Lorraine, Dept Surg, Nancy, France
[16] Ctr Henri Becquerel, Dept Med Oncol, Rouen, France
[17] Unicanc, Hlth Data & Partnership Dept, Paris, France
[18] Montpellier Univ, Inst Canc Montpellier, Dept Surg, Montpellier, France
[19] Univ Montpellier, Univ Hosp Nimes, IDESP Inst Desbrest Epidemiol & St Publ, Dept Med Oncol,UMR,UA11,INSERM, Montpellier, France
[20] 208 Ave Apothicaires, F-34000 Montpellier, France
关键词
Neoadjuvant; Cytoreduction; Survival; Prognosis; Propensity score; NEOADJUVANT CHEMOTHERAPY CYCLES; SURGICAL CYTOREDUCTION; OPEN-LABEL; SURVIVAL; NUMBER; MULTICENTER; BEVACIZUMAB; IMPACT; TRIAL;
D O I
10.1016/j.ygyno.2022.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Interval debulking surgery is recommended after 3-4 cycles (standard IDS) of neoadjuvant chemo-therapy (NACT) for epithelial ovarian cancer (EOC) not able to received upfront complete debulking surgery. However, real world practices frequently report performing IDS after >= 5 NAC cycles (delayed IDS). The aim of this work was to evaluate the impact on survival of the number of NACT cycles before IDS. Methods. We identified from a French national database, women with newly diagnosed EOC who underwent IDS from January 2011 to December 2016. Progression free survival (PFS) and overall survival (OS) were com-pared using Cox model with adjustments for confounding factors provided by two propensity score methods: in-verse probability of treatment weighting (IPTW) and matched-pair analysis. Results. 928 patients treated by IDS for which our propensity score could be applied were identified. After a median follow-up of 49.0 months (95% CI [46.0;52.9]); from the IPTW analysis, median PFS was 17.6 months and 11.5 months (HR = 1.42; CI 95% [1.22-1.67]; p < 0.0001); median OS was 51.2 months and 44.3 months (HR = 1.29; CI 95% [1.06-1.56]; p = 0.0095) for the standard and delayed IDS groups. From the matched-pair analysis (comparing 352 patients for each group), standard IDS was associated with better PFS (HR = 0,77; CI 95% [0.65-0.90]; p = 0.018) but not significantly associated with better OS (HR = 0,84; CI 95% [0.68-1,03]; p = 0.0947). Conclusions. Carrying IDS after >= 5 NACT cycles seems to have a negative effect on patients survival. The goal of IDS surgery is complete resection and should not be performed after >3-4 NACT cycles.(c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:11 / 21
页数:11
相关论文
共 38 条
[31]   Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined? [J].
Stoeckle, Eberhard ;
Boubli, Benjamin ;
Floquet, Anne ;
Brouste, Veronique ;
Sire, Marie ;
Croce, Sabrina ;
Thomas, Laurence ;
Guyon, Frederic .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2011, 159 (02) :407-412
[32]   PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline [J].
Tew, William P. ;
Lacchetti, Christina ;
Ellis, Annie ;
Maxian, Kathleen ;
Banerjee, Susana ;
Bookman, Michael ;
Jones, Monica Brown ;
Lee, Jung-Min ;
Lheureux, Stephanie ;
Liu, Joyce F. ;
Moore, Kathleen N. ;
Muller, Carolyn ;
Rodriguez, Patricia ;
Walsh, Christine ;
Westin, Shannon N. ;
Kohn, Elise C. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (30) :3468-+
[33]   Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy? [J].
Thomas, Quentin Dominique ;
Quesada, Stanislas ;
D'Hondt, Veronique ;
Belaroussi, Ines ;
Laas, Enora ;
Classe, Jean-Marc ;
Fabbro, Michel ;
Colombo, Pierre-Emmanuel ;
Fiteni, Frederic .
BULLETIN DU CANCER, 2022, 109 (02) :197-215
[34]   Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline [J].
Vanderpuye, Verna D. ;
Clemenceau, Jean Rene, V ;
Temin, Sarah ;
Aziz, Zeba ;
Burke, William M. ;
Cevallos, Nixon Leonardo ;
Chuang, Linus T. ;
Colgan, Terence J. ;
del Carmen, Marcela G. ;
Fujiwara, Keiichi ;
Kohn, Elise C. ;
Nogales, Jose Enrique Gonzales ;
Konney, Thomas Okpoti ;
Mukhopadhyay, Asima ;
Paudel, Bishnu D. ;
Toth, Ico ;
Wilailak, Sarikapan ;
Ghebre, Rahel G. .
JCO GLOBAL ONCOLOGY, 2021, 7 :1032-1066
[35]   Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer [J].
Vergote, Ignace ;
Trope, Claes G. ;
Amant, Frederic ;
Kristensen, Gunnar B. ;
Ehlen, Tom ;
Johnson, Nick ;
Verheijen, Rene H. M. ;
van der Burg, Maria E. L. ;
Lacave, Angel J. ;
Panici, Pierluigi Benedetti ;
Kenter, Gemma G. ;
Casado, Antonio ;
Mendiola, Cesar ;
Coens, Corneel ;
Verleye, Leen ;
Stuart, Gavin C. E. ;
Pecorelli, Sergio ;
Reed, Nick S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) :943-953
[36]   Defining the limits of radical cytoreductive surgery for ovarian cancer [J].
Wright, Jason D. ;
Lewin, Sharyn N. ;
Deutsch, Israel ;
Burke, William M. ;
Sun, Xuming ;
Neugut, Alfred I. ;
Herzog, Thomas J. ;
Hershman, Dawn L. .
GYNECOLOGIC ONCOLOGY, 2011, 123 (03) :467-473
[37]   The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer [J].
Xu, Xia ;
Deng, Fei ;
Lv, Mengmeng ;
Chen, Xiaoxiang .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (02) :451-458
[38]   Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy? [J].
Yoneoka, Yutaka ;
Ishikawa, Mitsuya ;
Uehara, Takashi ;
Shimizu, Hanako ;
Uno, Masaya ;
Murakami, Takashi ;
Kato, Tomoyasu .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (05)